# UroGen Pharma Ltd. (URGN): MoatMap facts

As of 27 Oct 2026. Research data, not investment advice.

As of 27 Oct 2026, MoatMap's StockRank for UroGen Pharma Ltd. (URGN) is 35/100, ranked against 24,000+ stocks in 35 markets (Quality 35, Value 25, Momentum 64, each scored against its sector).

- StockRank: 35/100, a percentile across 24,000+ stocks in 35 markets (100 is best).
- Quality 35, Value 25, Momentum 64: each a 0-100 percentile within Healthcare.
- Position: #17,211 overall, #1,494 in Healthcare.
- Listing: United States, NGM; Healthcare / Biotechnology.
- Last close: 34.04 USD on 26 Oct 2026.
- Insider filings, last 180 days: directors sold USD 3.9M.

Source: https://moatmap.ai/stock/URGN
How the scores work: https://moatmap.ai/methodology
Does StockRank work? The public record: https://moatmap.ai/decile-tracker